Life Sciences and Health Care Publications
Through thought-provoking publications, surveys and reports as well as insightful commentary, we deliver innovative, practical knowledge which companies can use to improve their overall business performance. Our network of research professionals and senior consultants can identify, analyse and help explain the issues critical to businesses across a variety of industries.
Recent thought leadership
- China's Biotech Parks – Leveraging the ecosystem for success
This whitepaper presents the current development conditions of Chinese biopharmaceutical industrial parks ("BPIPs"), summarizes common local support policies, and discusses how biopharma enterprises can use industrial parks and related policies to map out entry strategies or re-improve their layouts in China.
- Safeguarding Biopharma R&D – New heights in China's human genetic resources management
Optimizing human genetic resources (HGR) governance and adopting a data-driven operating model are critical for pharmaceutical companies in China's changing regulatory environment.
- Internet Hospitals in China: The new step into digital healthcare
This report examines how internet hospitals thrive under the 2030 Health China Planning Outline and COVID-19, and puts forward six issues and solutions for internet hospitals and with giving a panorama of it.
- 2021 Global Health Care Outlook: Accelerating industry change
The report looks at six issues driving change in the health care sector and present questions and actions health leaders should consider in the coming year. How stakeholders analyze, understand, and respond to these issues will shape their ability to navigate from recovering to thriving in the post-pandemic “new normal” and advance their journey along the path to the Future of Health.
- Chinese Medical Device Industry: How to thrive in an increasingly competitive market?
The whitepaper examines how foreign brands can enter the Chinese market by adopting an "In China, For China" strategy amid a changing regulatory environment and increasingly competitive landscape.
- 2021 China LSHC Industry Survey Results: ‘State of Industry’
To understand pharmaceutical & healthcare players' situation in China after a year the Covid-19 crisis outbreak, Deloitte took the survey to understand their 2020 outcome and outlook for 2021, and provided the industry insights and predictions.
- Biotech-in-a-box™: How to ‘ACE’ geographical expansion in Europe, A three-step game plan for biotech
Based on Deloitte's experience helping biotech companies navigate geographical expansion, this report defines an ACE framework - three steps to effectively assess market potential, select the most appropriate go-to-market options, and choose the best route to successfully establish presence in Europe.
- China Aesthetic Medicine Market Outlook Report
The report examined the different aspects of China's aesthetic medicine industry, including consumer demand, value chains, marketing approaches, and financing sources. The report also reveals five prevailing trends that will drive industry development, with "light" aesthetic medicine becoming a strategic focus. Regulatory reform and reshuffling are set to reshape the market landscape by raising quality and practice standards, as the sector enters a mature phase of development.
- Trends in Talent Incentives at Social Medical Service Institutions
The report focuses on "long-term incentive trends in the listed medical service industry" and "comprehensive incentives for top talent in social medical service institutions". It elaborates on current practices in talent incentives in China's medical service industry and suggests a framework for the implementation of talent strategies.
- China as a digital transformation sandbox: A prescription for pharma multinationals
According to the report, China's emerging digital healthcare ecosystem is empowering innovative commercial models in the pharma industry. New offerings, engagement models and technologies are being rapidly tested in the Chinese market, and companies are exploring digital solutions to address consumers' unmet needs.
- New Medical Reform in China: Pharma Companies' Tax Challenges, Opportunities and Responses
This article elaborates on the tax challenges, opportunities and response strategies for pharmaceutical enterprises.
- How pharma companies can address the pharmaceutical retail market transformations in China
In the whitepaper, the Deloitte China Life Sciences & Health Care (LSHC) Team explores how pharmaceutical companies can address the retail market evolution in China by analyzing three structural market changes and four key industry transformations.
- Six predictions for China's pharma & healthcare sector
The coronavirus outbreak will likely lead to profound changes to the dynamics of China healthcare industry. These changes could include massive investment in disease prevention infrastructure, the accelerated digital transformation of healthcare delivery models, a re-visiting of pharmaceutical companies pipeline strategies, as well as the adoption of advanced technology healthcare solutions. Deloitte makes six predictions in the report and sets out the implications for industry players.
- COVID-19: Pharma Industry Survey Results
With the breakout of COVID-19, Deloitte China Life Sciences & Health Care Industry team initiated a survey to understand the virus impact on China pharmaceutical industry and measure the longer-term impact this could eventually have on their business model and operating processes. We hope this report supports your business decisions during this special period.
- Winning in the cell and gene therapies market in China
The reports aims to cover the key factors and trends defining the China cell and gene therapies (CGT) industry. When innovation becomes an ever important winning strategy, the CGT eco-system in China with buoyant investors, companies, and researchers all eager to shape – and eventually benefit from – is already leading in many aspects around the globe. Hope you'll be enjoying to read this thoughtful report.
- 2020 China Life Sciences and Health Care M&A Trends
The report based on deal data, delves into uncertainties and challenges in M&A activities, especially M&A trends in subsectors such as drugs, biotech, medical service institutions and medical device manufacturers.
- 2020 Global Health Care Outlook
The challenges before the global health care sector are plenty. But so are the opportunities. As health care sector stakeholders prepare their road map for the future, it is important for them to have a panoramic view of what’s working and what’s not, what's redundant and what’s hot in their circles.
- 2020 Global Life Sciences Outlook
Biopharma and medtech organizations are in the fast lane, headed toward a future driven by evolving, data-driven technologies. As organizations strive to make sense of all the data signals, what metrics really matter in a rapidly changing world? To find the next generation of key performance indicators, there are several questions organizations could be asking: What can be done to reduce complexity in the patient experience? What is the next level of performance, and how to get there in the next year? Is there adequate visibility of products, costs, and operations to help make timely, informed decisions? Is there a need to acquire, build, or partner for additional capabilities? This outlook helps answer these questions and more.
- Winning in the future of medtech
As many of the technologies we once dreamed of are being explored, we do expect medical devices of the future to look significantly different than they do today. In this report, we explored what would the future medtech company look like in the changing landscape.
- Smart health communities and the future of health
The Deloitte Center for Health Solutions and Deloitte Center for Government Insights interviewed more than a dozen innovators using new approaches to engage people through communities—both virtual and geographic. The research found that harnessing the power of social networks and technology can enable smart health communities (SHCs) to empower individuals to manage their own health.
- Launching innovative biopharma in China
Deloitte introduces a series of four articles that break down the dynamics of a successful launch.
- 2019 Global life sciences outlook
Strategic transformation is at the core of life science companies as they build new business models for the future. To accelerate change, focus will be on developing innovative and relationship-driven partnerships and creating real value for patients.
- 2019 Global health care outlook
With financial sustainability, care delivery, patient centricity, digital transformation, and regulatory compliance at the top of the agenda, health care sector leaders need to collaborate with all stakeholders—both within the health care ecosystem and those in converging industries—as they look to shape the future of health care and establish a sustainable smart health community.
- Survey finds biopharma companies lag in digital transformation
The life sciences industry's commitment to digital transformation is increasing, but few organizations are digitally maturing. This report illustrates how companies can take an enterprisewide approach to digital transformation.
- China Medical Cosmetology O2O Market Analysis
Building upon status quo description, in-depth data analysis, competition pattern and cases study, this report provides a comprehensive analysis on trends, opportunities and challenges of China medical cosmetology O2O industry.
- Trends in integrated elderly care and medical services in China - exploring "the last mile" of healthy aging
Building upon status quo description, in-depth data analysis and cases study, this report provides a comprehensive analysis on trends, opportunities and challenges of China elderly care services and healthcare industry.
- Embrace Healthcare Revolution: Strategically moving from volume to value
The report analysis the China health strategies and discuss the opportunities and challenges of China Healthcare industry, hoping to help build a long-term joint health ecosystem in China.
- Analysis of investment and financing strategies for private hospitals
In order to better understand the financing status and future trend of private hospitals, this report combines sample survey data of 23 private hospitals to analyse the demand gap, challenges and financing purposes of private hospitals, hoping to provide valuable reference for the future financing strategy of private hospitals and improve their whole services capabilities.
- 2017 China Life Sciences and Healthcare Investment Promotion Report
Building upon in-depth investigation and suggestions from enterprises, this report provides a comprehensive analysis on opportunities and challenges of China life sciences and healthcare industry.
- 2018 global life sciences outlook
This report explores the major trends that are expected to impact life sciences companies in 2018 as they aim at improving their ecosystem, and suggests ways to meet the opportunities and challenges.
- Life Sciences and Health Care Predictions 2022
This report presents an optimistic view of the future, calling businesses to awaken to the possibilities that lie ahead and evaluates evidence in 2017 and provide six new predictions of the life sciences and health care ecosystem might look like in 2022 and the key constraints to overcome.
- 2018 global health care sector outlook
This 2018 outlook reviews the current state of the global health care sector; explores trends and issues impacting health care providers, governments, other payers, and patients; and suggests considerations for stakeholders as they seek to deliver high-quality, cost-efficient, smart health care.
- 2017 global health care sector outlook
This 2017 outlook reviews the current state of the global health care sector; explores trends and issues impacting sector organizations; and suggests considerations for stakeholders as they seek to deliver cost-effective, high-value health care.
- 2017 Global life sciences outlook
Explore our look at the current global issues impacting the global life sciences sector and considerations for stakeholders as they prepare for 2017.
- “Two Invoice System” —— Survive through Change and Develop through Exploration
The purpose of this article is to show the background of the new policy, features of industries affected and measures to encounter these changes.
- New Healthcare Reform in a New Era: Challenges for Multinational Pharmaceutical Companies and Corresponding Countermeasures to be Taken
This report analysis MPCs challenges and opportunities under the healthcare reform environment.
- Excellence in Medical Affair: Recent trends in China Medical Affairs and Outcomes from China Medical Affairs Survey 2016
This report summarizes the key environmental drivers to the survey findings, and provides point of view on how pharma companies should react to such dynamics.
- China’s changing pharmaceutical E-commerce market
This report predicts the development of pharma E-commerce and online medical, as well as the evolution of healthcare ecosystem in 3-5 years.
- China Pharmaceutical Internet +: Storm Brewing, Coming into Play
This report predicts the development of pharma E-commerce and online medical, as well as the evolution of healthcare ecosystem in 3-5 years.
- Pharmaceutical R&D Trends in China: Opportunity and Influence for Localized Development
This report delves into the current status as well as future trends of China pharmaceutical R&D industry, and explains the strategic implications for multinational pharmaceutical companies, who should consider more localized R&D approaches to address new opportunities and challenges.
- China's healthcare provider market: Riding the waves of reform
This report delves into the current status as well as future trends of healthcare industry, and offers strategies that both private and public hospitals can employ to adapt to the changing industry dynamics.
- 2015 Global health care sector outlook
This report examines the current issues impacting the global health care sector, provides a snapshot of activity in a number of geographic markets, and suggests considerations for stakeholders as they look ahead to 2015.
- 2015 Global life sciences sector outlook
The report outlines some of the top issues facing the global life sciences sector, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2015 and beyond.
- Healthcare and life sciences predictions 2020
The report is based on an observation of trends, events and bold steps that, if accelerated over the next five years and beyond, will paint a picture of a very different world.
- China senior housing — Now and the future
Exploring the opportunities and risks of investment in China's senior housing market and the trends likely to be seen in the near future
- Fortune favors the bold: Unlocking the future of China’s pharmaceutical market
Exploring the key events of the past 24 months in China's health care market and four key themes pharmaceutical companies should consider as they think about their future in China.
- 2014 Global health care outlook
The report examines the current state of the global health care sector, provides a snapshot of activity in a number of geographic markets, and suggests considerations for stakeholders as they address funding, cost, and other issues while seeking to grow revenue and market share in 2014 and beyond.
- 2014 Global life sciences outlook
The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
- Transforming medical affairs in China
Rethinking the role and effectiveness of the Medical Affairs function has become an urgent priority for pharmaceutical companies in China. The report presents our perspective on these challenges and how they can be successfully overcome.